This systematic review and network meta-analysis aimed to evaluate the comparative efficacy of SGLT2 inhibitors against GLP-1 receptor agonists concerning cardiovascular and renal outcomes, stratified by key clinical characteristics such as baseline renal function and cardiovascular risk to inform precision medicine in the management of type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.